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Abstract
Background: Unmethylated cytosine-guanine (CpG) motif-containing oligodeoxynucleotides (ODNs) have been
well characterized as agonists of Toll-like receptor 9 (TLR9). ODNs with a phosphorothioate (PTO) backbone have
been studied as TLR9 agonists since natural ODNs with a phosphodiester (PD) backbone are easily degraded by a
serum nuclease, which makes them problematic for therapeutic applications. However, ODNs with a PTO backbone
have been shown to have undesirable side effects. Thus, our goal was to develop nuclease-resistant, PD ODNs that
are effective as human TLR9 (hTLR9) agonists.
Results: The sequence of ODN2006, a CpG ODN that acts as an hTLR9 agonist, was used as the basic CpG ODN
material. The 3’-end modification of ODN2006 with a PD backbone (PD-ODN2006) improved its potential as an
hTLR9 agonist because of increased resistance to nucleolytic degradation. Moreover, 3’-end modification with
oligonucleotides showed higher induction than modification with biotin, FITC, and amino groups. Further,
enhancement of hTLR9 activity was found to be dependent on the number of CpG core motifs (GTCGTT) in the
PD ODN containing the 3’-end oligonucleotides. In particular, ODN sequences consisting of two to three linked
ODN2006 sequences with a PD backbone (e.g., PD-ODN2006-2006 and PD-ODN2006-2006-2006) acted as effective
agonists of hTLR9 even at lower concentrations.
Conclusions: This study showed that PD-ODN2006-2006 and PD-ODN-2006-2006-2006 can be used as potentially
safe agonists for hTLR9 activation instead of CpG ODNs with a PTO backbone. We propose these CpG ODNs
consisting of only a PD backbone as a novel class of CpG ODN.
Background
Unmethylated cytosine-phosphate-guanine (CpG) motifs
are considered to be pathogen-associated molecular pat-
terns because of their abundance in microbial genomes
but scarcity in vertebrate ones [1]. Short, single-
stranded, synthetic oligodeoxynucleotides with CpG
motifs (CpG ODNs) can induce the Th1-type immune
response through interaction with Toll-like receptor 9
(TLR9), a member of the Toll-like family of pattern-
recognition receptors [2-4]. Because Th1-type cytokines
such as IFN-g and IL-12 can inhibit the Th2-type
response [5,6], CpG ODNs are thought to have potential
for various immune therapies such as for cancer,
asthma, pollinosis, and infectious diseases [7-9].
To date, at least four different types of immune-stimu-
latory CpG ODNs with distinct structural and biological
characteristics have been reported [10]. The class A
CpG ODNs consist of phosphodiester (PD), CpG-con-
taining, palindromic motifs with phosphorothioate
(PTO), poly-G motifs at both the 5’ and 3’ ends. CpG
ODNs in this class can induce high levels of interferon-
a (IFN-a) production in plasmacytoid dendritic cells
(pDCs), but are weak stimulators of TLR9-dependent
NF-B signaling [11]. On the other hand, the class B
CpG ODNs consist entirely of PTO backbones and do
not form palindromic structures. These ODNs can
strongly activate B cells through NF-Bs i g n a l i n gb u t
show no effect on IFN-a production [12,13]. The class
C CpG ODNs show an intermediate immune property
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CpG-containing palindromic motifs consisting of only a
PTO backbone [14]. Recently, a novel type of CpG
ODN called the P class, which has two palindromic
motifs with a PTO backbone, was reported to show
higher potential to produce IFN-a and activate NF-B
[15].
Natural PD-ODNs are susceptible to nuclease degra-
dation, which renders them inactive for TLR9 activation
in the free form. Therefore, all CpG ODNs classified
above partially or completely contain a PTO backbone
to increase resistance to nuclease degradation in the
serum [16-18]. However, the PTO backbone has been
reported to cause unwanted side effects such as unspeci-
fic binding to various proteins [19] and renal damage
[20]. Therefore, because of safety considerations, the
development of novel natural CpG ODNs consisting of
an entirely PD backbone is desirable. Furthermore, these
natural CpG ODNs should be able to strongly activate
TLR9-dependent NF-B signaling. To develop such a
CpG ODN, we examined the effects of the sugar back-
bone, the sequence of the CpG motif, and modification
of both terminals in CpG ODNs on NF-B activation.
We found that a series of linked PD sequences of
ODN2006 (a class B agonist of hTLR9) has the potential
to resist nuclease degradation and to activate NF-B
through TLR9 at even lower concentrations than are
known for PTO ODNs.
Results
Natural CpG ODNs consisting of a PD backbone have no
potential to activate TLR9 because of degradation
To develop natural CpG ODNs with a PD backbone
that are capable of strong human TLR9 activation, the
ODN2006 sequence, a well-known class B agonist of
hTLR9 [13], was used as a basic sequence for designing
CpG ODNs. TLR9 activation was assessed by relative
NF-B activation in human TLR9-expressing cells
(293XL-hTLR9), since TLR9 activation by CpG ODNs
leads to activation of NF-B[ 2 1 ] .W es y n t h e s i z e da n
ODN2006 sequence consisting of either a PD or PTO
backbone (PD-ODN2006 and PTO-ODN2006, respec-
tively) (Table 1) and examined the effect of the back-
bone composition on NF-B activity. PD-ODN2006
showed little potential for activating TLR9, as demon-
strated by the increased NF-B activity, whereas PTO-
ODN2006 significantly activated NF-Bi nad o s e -
dependent manner (Figure 1A). Identical to previous
reports on the susceptibility of natural PD ODNs to
nuclease degradation [16-18], PD-ODN2006 likely
showed low potential for activating TLR9 because of
degradation in the serum (Figure 1B). In contrast, PTO-
Table 1 Oligodeoxynucleotide sequences examined in this study
ODNs Sequences (5’®3’)
PD-ODN2006 TCGTCGTTTTGTCGTTTTGTCGTT
PTO-ODN2006 tcgtcgttttgtcgttttgtcgtt
PTO-ODN2006-GC tgctgcttttgtgcttttgtgctt
PTO-ODN2006-1GC tgctcgttttgtcgttttgtcgtt
PTO-ODN2006-2GC tcgtgcttttgtcgttttgtcgtt
PTO-ODN2006-3GC tcgtcgttttgtgcttttgtcgtt
PTO-ODN2006-4GC tcgtcgttttgtcgttttgtgctt
PTO-ODN2006-2,3,4GC tcgtgcttttgtgcttttgtgctt
PTO-ODN2006-2,3GC tcgtgcttttgtgcttttgtcgtt
PTO-ODN2006-2,4GC tcgtgcttttgtcgttttgtgctt
PTO-ODN2006-3,4GC tcgtcgttttgtgcttttgtgctt
PD-ODN2006-3’-A TCGTCGTTTTGTCGTTTTGTCGTT-CCTTCAGTGGGACC
PD-ODN2006-5’-A CCTTCAGTGGGACC-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-3’-B TCGTCGTTTTGTCGTTTTGTCGTT-GGTCCCACTGAAGG
PD-ODN2006-5’-B GGTCCCACTGAAGG-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-3’-A-2006 TCGTCGTTTTGTCGTTTTGTCGTT-CCTTCAGTGGGACC-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-3’-B-2006 TCGTCGTTTTGTCGTTTTGTCGTT-GGTCCCACTGAAGG-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-2006 TCGTCGTTTTGTCGTTTTGTCGTT-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-TCGTCGTT TCGTCGTTTTGTCGTTTTGTCGTT-TCGTCGTT
PD-ODN2006-TCGTCGTTTTGTCGTT TCGTCGTTTTGTCGTTTTGTCGTT-TCGTCGTTTTGTCGTT
PD-ODN2006-2006-2006 TCGTCGTTTTGTCGTTTTGTCGTT-TCGTCGTTTTGTCGTTTTGTCGTT-TCGTCGTTTTGTCGTTTTGTCGTT
PD-ODN2006-G5 TCGTCGTTTTGTCGTTTTGTCGTT-GGGGG
ODNs: oligodeoxynucleotides; PD: phosphodiester; PTO: phosphorothioate. Capital and lowercase letters in sequences indicate PD and PTO backbones,
respectively. Bold sequences indicate the PD-ODN2006 sequence.
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Page 2 of 9ODN2006 still remained as clear band after serum treat-
ment, but a high-molecular-weight band was also
observed (Figure 1B). This band could be attributable to
proteins binding to the PTO backbone rather than
being specifically associated with the PTO-ODN2006
sequences, since Brown et al. [19] also reported binding
of proteins to ODNs with PTO backbones. Our result
suggests that PTO-ODN2006 resists nuclease degrada-
tion, but that an unfavorable reaction may also be
occurring in the serum. Therefore, novel GpG ODNs
that can stimulate TLR9 activity need to resist nucleoly-
tic degradation as well as not react with serum proteins.
Peptide nucleic acid inhibits TLR9 activation
Peptide nucleic acids (PNAs), which have backbones com-
posed of repeated N-(2-aminoethyl)-glycine units linked by
peptide bonds, have been developed to solve the problem
of biological instability in short-stranded DNA or synthetic
ODNs [22]. Thus, we examined the potential of ODN2006
consisting of a peptide backbone (PNA-ODN2006) for
TLR9 activation. However, no enhancement of TLR9 activ-
ity was observed (Figure 1C). Interestingly, PD-ODN2006
showed higher potential when LyoVec, a cationic lipid, was
used as a carrier to prevent nucleolytic degradation, but the
carrier had no effect for PNA-ODN2006. This indicates
that the lack of TLR9 activation by PNA-ODN2006 is attri-
butable to PNA and that the sugar backbone of CpG ODN
is essential for TLR9 activation.
CpG ODNs activate TLR9 in a sequence-dependent
manner
Next, we tried to design novel CpG ODN sequences with
a higher potential for activating TLR9 than ODN2006. To
determine if mutation or deletion of CG units could
improve CpG ODN design, we prepared different mutants
of PTO-ODN2006 (Table 1) by replacing CG unit(s) with
GC unit(s) and then examined their potential. NF-B
activity was dramatically decreased by PTO-ODN2006-
GC, an ODN in which all four CG units had been replaced
with GC ones (Figure 1D), indicating the importance of
the CG units for TLR9 activation. Interestingly, the third
CG unit in PTO-ODN2006 appeared to be the most
important one, since lower activity was observed for PTO-
ODN2006-3GC than for the three other ODNs with a sin-
gle GC substitution (Figure 1D). Similarly, lower activity
was also observed for PTO-ODN2006-2,3,4GC, PTO-
ODN2006-2,3GC, and PTO-ODN2006-3,4GC, than for
PTO-ODN2006-2,4GC. This suggests that the position
and number of CG units in ODN2006 are critical for
TLR9 activation, and that neither mutation nor deletion of
the CG units can enhance activity.
Modification at the 3’-end of PD-ODN2006 improves TLR9
activation
Exonucleases cleave nucleotides one at a time from the
terminal end of a polynucleotide chain. Thus, we modi-
fied the PD-ODN2006 5’ and 3’ terminal ends using bio-
tin, FITC, and amino groups (-NH2) to examine whether
these changes would improve the potential for TLR9
activation. As shown in Figure 2A, modifications at the
3’-end of PD-ODN2006 enhanced NF-B activity rela-
tive to no modification of PD-ODN2006. However, no
significant change was observed by modifying the 5’-
end. To clarify why the 3’-modifications improved the
activity, we incubated the 3’-modified PD-ODN2006s in
s e r u ma n df o u n dt h a tt h e ys h o w e di m p r o v e dr e s i s t a n c e
to degradation (Figure 2B).
We further modified the PD-ODN2006s by adding
two 14-mer oligonucleotides (called A and B) consisting
of a PD backbone (PD-ODN2006-5’/3’-A and PD-
ODN2006-5’/3’-B, respectively) (Table 1). These ODNs
showed enhanced NF-B activity relative to the unmodi-
fied PD-ODN2006 (Figures 2A and 2B). Interestingly,
-+-+ serum
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Figure 1 Effect of ODN backbones and CpG motif on NF-B
activation. (A) 293XL-hTLR9 cells transfected with hTLR9-signaling
reporter plasmid were stimulated by PD-ODN2006 and PTO-
ODN2006 with various concentrations. n = 3, mean (sd). Statistical
significances are denoted as follows: *P < 0.05, **P < 0.01. (B)
Stability of PD-ODN2006 and PTO-ODN2006 in aqueous solution
with/without serum. The arrow indicates PTO-ODN-protein complex.
(C) PD-ODN2006 and PNA-ODN2006 (0.2 μM) were applied to cells
with/without LyoVec. n = 3, mean (sd). Statistical significances are
denoted as follows: *P < 0.05, **P < 0.01. (D) 0.1 μM of PTO-
ODN2006 mutants (1: PTO-ODN2006, 2: PTO-ODN2006-GC, 3: PTO-
ODN2006-1GC, 4: PTO-ODN2006-2GC, 5: PTO-ODN2006-3GC, 6: PTO-
ODN2006-4GC, 7: PTO-ODN2006-2,3,4GC, 8: PTO-ODN2006-2,3GC, 9:
PTO-ODN2006-2,4GC, 10: PTO-ODN2006-3,4GC) were applied to
cells. n = 3, mean (sd). All P values are shown relative to the PTO-
ODN2006, *P < 0.05, **P < 0.01.
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Page 3 of 9modification at the 5’-end also improved activity (Figure
2A). This seemed to be due to the presence of CG units
remaining after degradation, since molecules were
detected even after incubation in serum (Figure 2B).
PD-ODN2006 series acts as a novel type of TLR9 agonist
Since the addition of the 14-mer oligonucleotides to the
3’-end of PD-ODN2006 significantly improved stability
and led to increased NF-B activity, we examined the
effect of adding other oligonucleotide sequences to the
3’-end of PD-ODN2006. Three types of modified PD-
ODN2006 sequences were designed. PD-ODN2006-3’-
A-2006 and PD-ODN2006-3’-B-2006 were constructed
from an ODN2006 sequence extension at the 3’-end of
PD-ODN2006-3’-A and PD-ODN2006-3’-B, respectively
(Table 1). For these ODNs, oligonucleotides A and B
were linkers between the two PD-ODN2006s. As the
third modified sequence, PD-ODN2006-2006 comprised
two directly linked PD-ODN2006s. All three structures
increased NF-B activity in a dose-dependent manner
(Figure 2C). Although PD-ODN2006-3’-A-2006 and PD-
ODN2006-3’-B-2006 enhanced activity to a further
extent compared to PD-ODN2006-3’-A and PD-
ODN2006-3’-B at the same concentration (0.5 μM) (see
Figure 2A), PD-ODN2006-2006 was more effective than
PD-ODN2006-3’-A-2006 and PD-ODN2006-3’-B-2006
at every concentration. All three 3’-modified PD-
ODN2006s with oligonucleotides resisted nucleolytic
degradation as well as the other 3’-end modified PD-
ODN2006 (Figure 2D).
It has been reported that the GTCGTT sequence is a
core CpG motif for hTLR9 activation [23]. Thus, the
effect of the 3’-end extension of PD-ODN2006 by this
core motif was examined. PD-ODN2006-3’-TCGTCGTT
and PD-ODN2006-3’-TCGTCGTTTTGTCGTT contain
o n ea n dt w oc o r em o t i f ( s )a tt h e3 ’ end, respectively
(Table 1). As the PD-ODN2006 sequence contains three
core motifs, these CpG ODNs represented a total of four
and five core motifs. PD-ODN2006-2006 and PD-
ODN2006-2006-2006 also have six and nine core motifs,
respectively (Table 1). As shown in Figure 3A, the poten-
tial for TLR9 activation depended on the number of core
motifs. In particular, PD-ODN2006-2006-2006 enhanced
the activity even at a concentration of 0.01 μM. More-
over, PD-ODN2006-2006 showed much higher potential
than PD-ODN2006-3’-TCGTCGTTTTGTCGTT at con-
centrations below 0.1 μM.
Linked series of PD-ODN2006 (e.g., PD-ODN2006-
2006-2006) also showed higher potential than that
reported for PD-ODN2006-G5, the backbone of which
consists of PD entirely [24,25]. These differences were
especially significant at the lower concentrations (Figure
3A). A higher molecular band was observed for PD-
ODN2006-G5, which may be attributable to a supramo-
lecular structure formed by the poly-G tails [26]. How-
ever, none were observed for the ODNs consisting of
PD-ODN2006 in a series (Figure 3B). To examine
whether NF-B activation by PD-ODNs is mediated by
TLR9, we used 293XL-null cells. These TLR9-deficient
cells did not show any significant increase in NF-B
activity when stimulated either by PTO-ODN2006 or
our novel PD-ODNs (Figure 3C).
We also assessed the potential of PD-ODNs using B
lymphocyte Ramos-Blue cells. PD-ODN2006-2006 had
similar potential to PD-ODN2006-G5, but less than
PTO-ODN2006. However, the potential of PD-
ODN2006-2006-2006 was much higher than that of PD-
ODN2006-G5 and almost the same as PTO-ODN2006
(Figure 4A). In addition, PD-ODN2006-2006-2006 had
higher potential to induce IL-6 secretion in peripheral
blood mononuclear cells (PBMCs) than PD-ODN2006-
G5 and PTO-ODN2006, although no significant change
was observed (Figure 4B). We also examined the IL-6
secretion in plasmacytoid dendritic cells (CAL-1). For
PD-ODN2006-2006-2006, the secretion of IL-6 was
higher than PD-ODN2006-G5 and PTO-ODN 2006,
which was consistent with what was observed in the
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Figure 2 Effect of terminal modification and linker sequences
in PD-ODN2006 on NF-B activation. (A) 293XL-hTLR9 cells
transfected with hTLR9-signaling reporter plasmid were stimulated
by modified PD-ODN2006s (1: PD-ODN2006, 2: PD-ODN-3’-Biotin, 3:
PD-ODN-5’-Biotin, 4: PD-ODN-3’-FITC, 5: PD-ODN-5’-FITC, 6: PD-ODN-
3’-NH2, 7: PD-ODN-5’-NH2, 8: PD-ODN-3’-A, 9: PD-ODN-5’-A, 10: PD-
ODN-3’-B, 11: PD-ODN-5’-B) at a concentration of 0.5 μM. n = 3,
mean (sd). All P values are shown relative to the PD-ODN2006, *P <
0.05, **P < 0.01. (B) Stability of modified PD-ODN2006s in aqueous
solution with/without serum. (C) 293XL-hTLR9 cells transfected with
hTLR9-signaling reporter plasmid were stimulated by series
connection of PD-ODN2006 with/without linker sequences. n = 3,
mean (sd). (D) Stability of these PD-ODNs in aqueous solution with/
without serum.
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Page 4 of 9PBMCs. However, the secretion of IL-6 by the stimula-
tion of PBS and PD-ODN2006 was not detected in this
cell line (Figure 4C).
Discussion
Synthetic oligonucleotides in recent use are usually pro-
tected from degradation by modification of the
backbone, whereas natural CpG ODNs are readily
degraded by ubiquitous nucleases both in vivo and in
vitro [16-18]. The CpG ODNs developed in this study
consist of only a natural PD backbone, which may elimi-
nate the side effects introduced by the PTO backbone
modification. Moreover, by connecting two or three
simple ODNs, we obtained novel CpG ODNs with
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Figure 3 Effect of novel CpG-ODNs on NF-B activation in 293XL-hTLR9 cells and 293XL-null cells. (A) 293XL-hTLR9 cells transfected with
hTLR9-signaling reporter plasmid were stimulated by PD-ODN with an elevated number of CpG motifs. n = 3, mean (sd). All P values are shown
relative to the PD-ODN2006 with the same concentrations, *P < 0.05, **P < 0.01. (B) Stability of PD-ODNs in aqueous solution with/without
serum. The arrow indicates supramolecular structure of PD-ODN2006-G5. (C) NF-B activation by PD-ODNs (1: PD-ODN2006, 2: PD-ODN2006-
2006, 3: PD-ODN2006-2006-2006, 4: PD-ODN2006-G5, 5: PTO-ODN2006) in hTLR9 deficient cells (293XL-null) and hTLR9 expressing cells (293XL-
hTLR9 cells). Statistically significant results are denoted as follows: *P < 0.05, **P < 0.01.
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Page 5 of 9better nuclease tolerance and higher immunostimulatory
potential in hTLR9-dependent NF-B activation.
We used the sequence of a typical class B CpG ODN
(ODN2006) to develop novel agonists for human TLR9.
In our in vitro model system, it was shown that natural
PD-ODN2006 likely had very little potential for activat-
ing NF-B due to degradation by serum nucleases.
TLR9 activation requires the internalization of CpG
ODNs into the late endosome/lysosome of TLR9-
expressing cells for recognition. Therefore, protection of
the ODNs from degradation is an initial step in main-
taining their activity. Hence, PTO backbones are com-
monly used to protect the open ends of linear
oligonucleotides. Although PTO-ODN2006 demon-
strated much higher potential for TLR9 activation than
PD-OD2006, it was not a perfect candidate as an immu-
notherapeutic agent. The PTO backbone modification
led to nonspecific interactions between PTO-ODN2006
and serum proteins, as shown with the high-molecular-
weight band for this ODN, whereas no bands were
obtained for PD-ODN2006. This result also suggests
that the side effects of PTO-ODNs may be a product of
the backbone modification and may not be related to
the increased half-life.
PNA is a DNA analog in which the natural phospho-
diester backbone of DNA is replaced by a 2-aminoethyl-
glycine linkage. PNA modification is widely used to
increase the biological stability of short-stranded DNA
when developing antisense technology [22]. We exam-
ined the effect of the PNA-ODN2006 sequence, but no
significant increase in activity was observed. Haas et al.
suggested that the DNA sugar backbone (2’ deoxyribose)
determines TLR9 activation because they found that the
corresponding RNA ribo-oligonucleotides could not
activate TLR9 [27]. In our study, the inhibitory effect of
PNA-ODN also supports the suggestion that the 2’
deoxyribose in the DNA plays a crucial role in TLR9
activation.
We concluded from the decreased activity of the
mutated PTO-ODN2006 that all the CG units in
ODN2006 were essential for activation. Moreover, the
t h i r dC Gs e e m e dt ob et h em o s ti m p o r t a n tu n i tf o r
TLR9 activation. Hence, protection of the CG units
from degradation in natural PD-ODN2006 is crucial for
maintaining its immunostimulatory activity. Modifica-
tion of ODN2006 with either organic molecules at the
3’-end or oligonucleotides at the 3’-o r5 ’-ends enhanced
the stimulatory activity. This enhancement can be
explained by the increased resistance of the ODNs to
nuclease degradation. Although it has been reported
that free 5’ ends in CpG ODNs with a PTO backbone
are required for the activation of TLR9 [28,29], loss of
activity in 5’-modified PD-ODN2006 in this study was
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Figure 4 TLR9 activation by B lymphocytes, PBMC, and CAL-1
cells. (A) Activation of NF-B in human B lymphocyte cell lines,
Ramos-Blue cells, stably transfected with NF-kB/AP-1-inducible SEAP
reporter gene. n = 3, mean (sd). All P values are shown relative to
the PD-ODN2006: *P < 0.05, **P < 0.01. (B-C) IL-6 production
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dendritic cells CAL-1(C). The symbol # indicates that no cytokine
secretion was detected.
Meng et al. BMC Biotechnology 2011, 11:88
http://www.biomedcentral.com/1472-6750/11/88
Page 6 of 9attributed to degradation. When we modified PD-
ODN2006 with 14-mer oligonucleotides at the 5’-end,
there was still some potential to activate NF-B, with
some bands still present after serum degradation.
To further increase the immunostimulatory activity of
the 3’-modified PD-ODN2006, we next prepared a series
of linked PD-ODN2006 sequences (PD-ODN2006-3’-A-
2006 and ODN2006-3’-B-2006), which increased the
number of CG motifs in each oligonucleotide. Surpris-
ingly, PD-ODN2006-3’-B-2006 led to higher activity
than PD-ODN2006-3’-A-2006 at every concentration,
which indicated that the linker sequence can affect the
potential of CpG ODNs for NF-B activation. Finally,
we removed the linker, generating PD-ODN2006s such
as PD-ODN2006-2006 and PD-ODN2006-2006-2006.
The enhanced potential for NF-B activation obtained
by CpG-ODN2006-2006 compared with ODN2006-A/B-
2006 demonstrated that the linker sequences used in
this study inhibited the activation of TLR9. Moreover,
PD-ODN2006-2006-2006 showed much higher activity
than PD-ODN2006-2006, indicating that the number of
CG motifs played a key role in the activity. To verify
that the ODN2006-linked sequences activate NF-B
activation through the TLR9 pathway, we applied PD-
ODN2006-2006 into a 293XL-null cell line that does
not express hTLR9. Consequently, we observed no NF-
B activation in this cell line. Therefore, PD-ODN2006-
2006 is thought to indeed activate NF-Bt h r o u g ht h e
TLR9 pathway. Hence, these series of PD-ODN2006
sequences might be used as novel and effective TLR9
agonists.
To our knowledge, there are a few reports on nucle-
ase-resistant immunostimulatory CpG ODNs with
entirely PD backbones. Lee et al. [25] reported that the
conjugation of poly-guanosine (poly-G) sequences at the
3’-end of PD-CpG ODNs significantly enhanced TNF-a
and IL-12 production from mouse splenic dendritic
cells. Bartz et al. [26] modified PD-ODN2006 with poly-
G sequences and increased the cellular uptake and sti-
mulatory activity of PD-ODN2006 in human leukocytes.
They suggested that the increase in the activity resulted
from the enhanced cellular uptake, which was attributed
to the formation of ODN tetrads, G-Quadra structure.
We also observed a supramolecular structure for PD-
ODN2006-G5, as indicated by the presence of a high-
molecular-weight band from agarose electrophoresis.
However, no high-molecular-weight aggregate was
formed for PD-ODN2006-2006. Atomic force micro-
scopy also revealed that class A CpG ODNs with poly-G
sequences form a particle structure, while class B PTO-
ODN2006 forms a linear structure [30]. Clear bands of
PD-ODN2006-2006 and PD-ODN-2006-2006-2006
remained after serum degradation, indicating that the
series of natural PD-ODN2006s preserved the potential
for TLR9 activation due to enhanced stability. We also
speculate that the increase in the number of CG motifs
in the oligonucleotides played an important role in the
enhanced TLR9 activation potential. Our novel PD-
ODNs demonstrated higher NF-B activity in not only
the 293XL-hTLR9 model cell lines but also B lympho-
cyte cell lines (Ramos-Blue) when stimulated with PD-
ODN2006-2006 and PD-ODN2006-2006-2006.
In this study, we examined the production level of IL-
6 because our CpG ODNs are considered to have the
same linear structure, which is proved to activate only B
cells but not dendritic cells that produce IL-12 and type
I interferon, as class B CpG ODNs [12,13]. Our PD-
ODNs also showed a higher potential for the production
of IL-6. Therefore, our CpG - O D N sa r es u i t a b l ef o r
immunotherapeutic use.
Conclusion
T h ep u r p o s eo ft h i ss t u d yw a st od e v e l o ps a f ea n d
effective CpG ODNs consisting of a PD backbone for
hTLR9 activation. Our data indicate that 3’-modified
CpG ODNs consisting of a PD backbone are effective
at resisting nucleolytic degradation, and that the num-
ber of CpG core motifs strongly influence their poten-
tial as hTLR9 agonists. In particular, CpG ODNs with
linked PD-ODN2006 sequences (e.g., PD-ODN2006-
2006 and PD-ODN-2006-2006-2006) can act as effec-
tive and potentially safe agonists of hTLR9 at low
concentrations.
Methods
Cell cultures
293XL-hTLR9 cells stably expressing hTLR9 and
293XL-null cells were purchased from Invivogen (CA,
US). Cells were grown in high-glucose, Dulbecco-mod-
ified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 50 units/mL penicillin, 50
mg/mL streptomycin, and 10 μg/mL blasticidin at 37°C
in humidified air containing 5% CO2. Cells were
seeded in 48-well culture plates for transfection and
cell stimulation. A B lymphocyte cell line that stably
expresses an NF-kB/AP-1-inducible secreted embryo-
nic alkaline phosphate (SEAP) reporter gene, Ramos-
Blue cell line (Invivogen), was cultured in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented
with 10% (FBS), 2 mM L-glutamine, 50 units/mL peni-
cillin, and 50 mg/mL streptomycin. Peripheral blood
mononuclear cells (PBMCs) were purchased from Cel-
lular Technology Limited (OH, US) as frozen cells.
The procedures for the thawing of PBMCs were
adapted from the manufacturer’s protocol. The plas-
macytoid dendritic cell line, CAL-1 was maintained in
RPMI 1640 medium supplemented with 10% FBS as
indicated in the report [31].
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ODNs consisting of phosphodiester (PD) and phosphor-
othioate (PTO) backbones, and ODNs modified with
biotin, FITC, or amino groups (-NH2) were purchased
from Fasmac Inc. (Kanagawa, Japan). The ODNs were
diluted in sterilized water and stored at -20°C. Peptide
nucleic acid was purchased from Panagene (Daejeon,
Korea).
NF-B luciferase assay
To monitor transient NF-B activation, 293XL-hTLR9
cells and 293XL-null cells were seeded at 1 × 10
5 cells
per well and transiently transfected with pNiFty-luc (a
TLR9-signaling reporter plasmid, Invivogen) and
pGL4.74 (a Renilla luciferase gene containing plasmid,
Promega, WI, US), using LyoVec (Invivogen). After 24
h, cells were stimulated with oligonucleotides. These
cells were lysed using a passive lysis buffer after 24 h,
and lysates were assayed for luciferase activity using a
luminometer (TD-20/20, Promega) according to the
manufacturer’s instructions. The data were represented
as relative NF-B activity compared with that of non-sti-
mulated control cells.
B lymphocyte Ramos-Blue cells were seeded at a den-
sity of 2 × 10
6 cells/mL, and the cells were immediately
stimulated with 0.5 μM ODNs. Cell supernatants were
collected, and NF-B activation was examined by the
reporter gene SEAP expression levels using a spectro-
photometer at 620 nm.
Stability of oligodeoxynucleotides in serum
Twenty microliters of ODNs at a final concentration of
10 μM was incubated in an aqueous solution containing
20% FBS at 37°C for 16 h. All samples were subse-
quently treated with 2 μL of 250 mM EDTA for 2 min
at 80°C to quench the digestion reaction. The integrity
of the ODNs was then analyzed by gel electrophoresis
using a 4% agarose gel.
Measurement of IL-6 release from PBMC and CAL-1
After thawing, PBMCs were seeded in serum free med-
ium, CTL-test medium (Cellular Technology Limited),
at a density of 1.0 × 10
6 cells/mL. Cells were immedi-
ately stimulated with 0.5 μM ODNs. After 24 h of incu-
bation at 37°C, cell supernatants were collected and
stored at -20°C until further analysis. CAL-1 was seeded
at a density of 5.0 × 10
6 cells/mL and stimulated with
1.5 μM ODNs for 48 hours. Supernatants were collected
and stored at -20°C until further analysis. The level of
human IL-6 in the media was determined by enzyme-
linked immunosorbent assay (ELISA) using the Ready-
SET-Go! Set (eBiosciences, San Diego, CA). The proce-
dures for the ELISA for IL-6 were adapted from the
manufacturer’s protocol.
Statistical Analysis
Stoic analysis was performed using Student’s t-test. A p-
value less than 0.05 was considered to be statistically
significant.
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